1. Home
  2. CLPS vs CVM Comparison

CLPS vs CVM Comparison

Compare CLPS & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

N/A

Current Price

$1.02

Market Cap

31.6M

Sector

Technology

ML Signal

N/A

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

N/A

Current Price

$1.69

Market Cap

30.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLPS
CVM
Founded
2005
1983
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.6M
30.1M
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
CLPS
CVM
Price
$1.02
$1.69
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.5K
★ 100.5K
Earning Date
03-06-2026
05-13-2026
Dividend Yield
★ 14.76%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $264,033.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 65.45
52 Week Low
$0.80
$0.89
52 Week High
$1.88
$10.83

Technical Indicators

Market Signals
Indicator
CLPS
CVM
Relative Strength Index (RSI) 57.32 58.89
Support Level $0.82 $0.95
Resistance Level $1.12 $1.76
Average True Range (ATR) 0.04 0.09
MACD -0.01 0.01
Stochastic Oscillator 71.25 72.25

Price Performance

Historical Comparison
CLPS
CVM

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Share on Social Networks: